U.S. Markets closed

Takeda Pharmaceutical Company Limited (TKPYY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
23.81+0.14 (+0.57%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close23.67
Bid0.00 x
Ask0.00 x
Day's Range23.71 - 23.81
52 Week Range19.96 - 25.15
Avg. Volume92,445
Market Cap36.94B
PE Ratio (TTM)32.02
Earnings DateN/A
Dividend & Yield0.78 (3.32%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Takeda and Cognition Kit partner in study to pilot wearable software in patients with Major Depressive Disorder (MDD)

    CAMBRIDGE, England and DEERFIELD, Ill., Feb. 23, 2017 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition Kit Limited, a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Limited, announced a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD). Depression (MDD) is the leading cause of disability worldwide, affecting an estimated 350 million people of all ages.1 Cognitive problems are common in major depression and may be under recognized by both patients and clinicians.2,3 Cognitive testing provides the opportunity to detect and understand the pattern of cognitive symptoms in patients with MDD.

  • PR Newswire8 days ago

    Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease

    OSAKA, Japan, Feb. 17, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced that interim findings from the ongoing, open-label GEMINI long-term safety (LTS) study were presented during the 12th Congress of European Crohn's and Colitis Organisation (ECCO) in Barcelona, Spain, February 15-18, 2017. Data presented from two five-year interim analyses of effectiveness and safety in patients with moderate to severely active ulcerative colitis (UC) and Crohn's disease (CD) indicated that long-term treatment of vedolizumab in responders was associated with long-term clinical response and remission, in addition to health-related quality of life (HRQL) improvements for patients over a five-year period.

  • American City Business Journals9 days ago

    Raleigh's PRA Health Sciences gains 60 employees after Takeda deal

    Following a partnership announced in September , Raleigh-based contract research organization PRA Health Sciences and pharmaceutical giant Takeda Pharmaceutical Company Limited have expanded their deal to Japan. PRA (PRAH) and Takeda (TKPHF) will form a joint venture for the deal’s expansion, which they will each hold 50 percent of, the companies announced. The joint venture will focus on clinical trials and drug safety services.